Screening and Prevention of Type 1 Diabetes: Where Are We?
dc.contributor.author | Simmons, Kimber M. | |
dc.contributor.author | Sims, Emily K. | |
dc.contributor.department | Pediatrics, School of Medicine | |
dc.date.accessioned | 2024-11-11T11:06:46Z | |
dc.date.available | 2024-11-11T11:06:46Z | |
dc.date.issued | 2023 | |
dc.description.abstract | A diagnosis of type 1 diabetes (T1D) and the subsequent requirement for exogenous insulin treatment is associated with considerable acute and chronic morbidity and a substantial effect on patient quality of life. Importantly, a large body of work suggests that early identification of presymptomatic T1D can accurately predict clinical disease, and when paired with education and monitoring, can yield improved health outcomes. Furthermore, a growing cadre of effective disease-modifying therapies provides the potential to alter the natural history of early stages of T1D. In this mini review, we highlight prior work that has led to the current landscape of T1D screening and prevention, as well as challenges and next steps moving into the future of these rapidly evolving areas of patient care. | |
dc.identifier.citation | Simmons KM, Sims EK. Screening and Prevention of Type 1 Diabetes: Where Are We?. J Clin Endocrinol Metab. 2023;108(12):3067-3079. doi:10.1210/clinem/dgad328 | |
dc.identifier.uri | https://hdl.handle.net/1805/44463 | |
dc.language.iso | en_US | |
dc.publisher | Oxford University Press | |
dc.relation.isversionof | 10.1210/clinem/dgad328 | |
dc.relation.journal | The Journal of Clinical Endocrinology and Metabolism | |
dc.rights | Publisher Policy | |
dc.source | PMC | |
dc.subject | Type 1 diabetes | |
dc.subject | Screening | |
dc.subject | Prevention | |
dc.subject | Pediatric | |
dc.title | Screening and Prevention of Type 1 Diabetes: Where Are We? | |
dc.type | Article | |
ul.alternative.fulltext | https://pmc.ncbi.nlm.nih.gov/articles/PMC11491628/ |